Researchers in the study found ibSium demonstrated a significant effect in the improvement of gastrointestinal symptoms in subjects suffering from Irritable Bowel Syndrome with constipation (IBS-C). ibSium is a product containing a patented strain of Saccharomyces cerevisiae, selected by Lesaffre among thousands of proprietary strains and registered with the French National Collection of Microorganism Cultures as CNCM I-3856.
The study was a multi-centric randomized double-blind placebo-controlled trial conducted under the supervision of Professor Robin Spiller, an international specialist in gastroenterology recognized for his background on IBS, in a group of 379 healthy volunteers presenting IBS symptoms according to the Rome III criteria. For 12 weeks, each of them consumed either 2 x 500 mg of ibSium or a placebo every day and had to complete an evaluation form of their IBS symptoms daily. One of the main findings throughout the study was that IBS-C subjects consuming ibSium experienced a significant relief of their abdominal pain and discomfort versus the placebo group (p = 0.04). They also felt significantly less bloated (p=0.01).
“With this new official publication, ibSium becomes the best substantiated natural ingredient with a clinically proven effect on IBS symptoms, as highlighted by the results of clinical studies performed in a total of 600 volunteers as well as a large scale consumer study run by prescribing physicians in over 1160 volunteers presenting symptoms of IBS,” said Peter Jüsten, managing director of Lesaffre Human Care. Earlier this year, the findings of a first clinical study using ibSium were published in the journal Digestive and Liver Disease (ibSium was called Lynside Pro GI+ in this paper and has been rebranded since then).
For more information:www.lesaffrehumancare.com